


C L A I M S

1. A method for manufacturing hydrogen sulphate (alpha S) of the alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester (clopidogrel hydrogen sulphate) of formula I



(I)

in crystalline Form I, *characterized in* that the compound of formula I is separated out of a solution of clopidogrel in the form of the free base or salt in a solvent selected from the series of primary, secondary or tertiary C1-C5 alcohols or their esters with C1-C4 carboxylic acids, or optionally of mixtures thereof.

2. The method according to claim 1, *characterized in* that the compound of formula I is crystallised out of a solution of clopidogrel hydrogen sulphate by cooling down.
3. The method according to claim 1, *characterized in* that the compound of formula I is precipitated out of a solution of the base or of its salt by adding of 0.6 to 1.1 equivalent of sulphuric acid.
4. The method according to claim 3, *characterized in* that the compound of formula I is precipitated out of a solution in a C1 to C5 alcohol.
5. The method according to claim 4, *characterized in* that the precipitation is performed out of a solution in 2-propanol.

6. The method according to claim 5, *characterized in* that the precipitation is performed at a temperature between -5 and 15 °C and the solution is inoculated with crystals of Form I.
7. Clopidogrel hydrogen sulphate of formula I, manufactured by the method according to the claim 6, having the contents of 98 % of crystalline Form I at minimum.